These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 28335509)

  • 1. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.
    Chang JC; Kundranda M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
    Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
    Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
    van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
    Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
    [No Abstract]   [Full Text] [Related]  

  • 5. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma.
    Nakata B; Chung YS; Nishimura S; Nishihara T; Sakurai Y; Sawada T; Okamura T; Kawabe J; Ochi H; Sowa M
    Cancer; 1997 Feb; 79(4):695-9. PubMed ID: 9024707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma.
    Zhuge X; Guo C; Chen Y; Feng L; Jia R; Zhao Y; Sun K; Wang Z; Chen X
    Pancreas; 2018; 47(10):1290-1295. PubMed ID: 30308534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
    Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
    J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
    Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.
    Laeseke PF; Chen R; Jeffrey RB; Brentnall TA; Willmann JK
    Radiology; 2015 Dec; 277(3):644-61. PubMed ID: 26599925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma.
    Nakagawa S; Yamashita YI; Umezaki N; Yamao T; Okabe H; Imai K; Nitta H; Hashimoto D; Chikamoto A; Baba H
    Pancreas; 2018 Oct; 47(9):1130-1134. PubMed ID: 30161074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
    Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of CA-19-9 in pancreatic carcinoma.
    Nakao A; Oshima K; Nomoto S; Takeda S; Kaneko T; Ichihara T; Kurokawa T; Nonami T; Takagi H
    Semin Surg Oncol; 1998; 15(1):15-22. PubMed ID: 9671952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.
    Goh SK; Gold G; Christophi C; Muralidharan V
    ANZ J Surg; 2017 Dec; 87(12):987-992. PubMed ID: 28803454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational biomarkers for pancreatic adenocarcinoma: where do we stand?
    Datta J; Vollmer CM
    South Med J; 2014 Apr; 107(4):256-63. PubMed ID: 24937521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.